Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

Statistical and Data Coordinating Center (SDCC) for Clinical Research in Infectious Diseases

Active
RFP-NIAID-DMID-75N98026R00169Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Institute of Allergy and Infectious Diseases (NIAID) is issuing a Small Business Sources Sought notice to identify qualified small business sources capable of establishing and managing a Statistical and Data Coordinating Center (SDCC). The SDCC will support extramural clinical research programs, specifically focusing on Phase 0-4 clinical trials for therapeutics, vaccines, and diagnostics related to infectious, immunologic, and allergic diseases. Key requirements include 21 CFR Part 11-compliant data management, statistical design and analysis, specimen tracking, and the integration of AI tools subject to human review and quality control. The government anticipates a single contract award with a maximum duration of seven years, estimating an initial requirement of 60 full-time equivalents per year with options for up to 90 additional FTEs. Interested small businesses must submit a tailored capability statement by September 30, 2026, demonstrating their expertise in clinical data systems, regulatory compliance, and project management. This notice is intended for market research to determine the appropriate acquisition method and potential set-asides and is not a formal solicitation for proposals.

General Info

NIAID seeks small businesses to manage a clinical research Statistical and Data Coordinating Center.

Agency

Department Of Health And Human Services → National Institutes Of Health NiaidView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

MD, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseSources Sought
Posted

Sources Sought

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Niaid
Contacts2 people available
OfficeBETHESDA, MD, 20892, USA
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health Niaid
View Agency Profile
Office AddressBETHESDA, MD, 20892, USA
Contacts

Full Description

Show more

Sources Sought Notice Information


Introduction


This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding:


    1. the availability and capability of qualified small business sources;
    2. whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and
    3. their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition.


Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice.



Background


Research supported and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS), strives to understand, treat and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten millions of human lives. This mission is driven by two strategic aims: addressing major infectious diseases, including emerging and chronic infections, and tackling immunologic and allergic disorders. The NIAID Division of Microbiology and Infectious Diseases (DMID) supports extramural research to control and prevent diseases caused by virtually all infectious agents. This includes basic and applied research to develop and evaluate therapeutics, vaccines, medical devices, and diagnostics, which are funded through a variety of research grants and contracts.



Through multiple grant- and contract-funded research programs, NIAID supports a broad range of clinical research, including single-center and multi-center Phase 0-4 clinical trials of therapeutics, including both novel agents and repurposed therapies; vaccines, new vaccine formulations, schedules, and modes of delivery; natural history and cohort studies for pathogens of interest; and evaluation of novel diagnostics for selected infectious diseases. These clinical research activities are focused on the improved diagnosis, treatment, and prevention of emerging, infectious, and chronic diseases for public health priorities that address the needs of the United States (U.S.) population.



Purpose and Objectives


The U.S. Government has a requirement for the establishment and management of a Statistical and Data Coordinating Center (SDCC) to support DMID’s extramural clinical research programs.



Project Requirements


The project requirements of the SDCC include: 21 CFR Part 11-compliant clinical data management systems for the collection, storage, management, reporting and quality control of study data; preparation of study-related materials; clinical study websites; statistical design and analysis expertise; data management user training; support of study operations, clinical site capability assessment for data management; electronic specimen tracking system; data storage facility; and project/site management.



Anticipated Period of Performance


The Government anticipates making one (1) contract award. It is anticipated that the duration of the contract will be a maximum of seven (7) years.



Other important considerations:


Where permissible and appropriate, incorporation of Artificial Intelligence (AI) across the functions of the SDCC are anticipated to be permitted, while enforcing safeguards for participant privacy and regulatory compliances, in alignment with NIH policies and guidances, including Office of Science Policy’s (OSP) Artificial Intelligence in Research: Policy Considerations and Guidance. Final decisions affecting clinical data shall remain subject to documented human review and quality control.



Respondents lacking the expertise to address all the technical requirements are encouraged to identify collaborations and partnerships that, through combined expertise, can address all these technical requirements.



Capability Statement/Information Sought


Interested Sources are expected to have the expertise, personnel, and facilities to meet the requirements of the project. Tailored Capability Statements submitted as a result of this notice shall demonstrate and document the offerors’ qualifications and experience, specifically providing evidence as to its capability to perform this requirement, with particular attention to the following technical areas:



  1. Ability to operate and maintain a state-of-the-art 21 CFR Part 11-compliant clinical data system for the collection, management, storage, and reporting of clinical and non-clinical data.
  2. Ability to ensure the accuracy, completeness, and timeliness of all data entered into the clinical data management system.
  3. Ability to provide clinical trial statistical design and analysis functions for Phase 0-4 clinical trials evaluating therapeutics, vaccines and devices for a wide variety of chronic and infectious diseases.
  4. Ability to conduct the preparation, writing, and distribution of the protocol and other study-related materials.
  5. Ability to communicate and collaborate with NIAID, grant recipients and contractors, and other study collaborators to facilitate clinical research activities.
  6. Ability to facilitate study operations and regulatory requirements through reporting and analytics, and facilitate NIAID’s requirements for oversight and performance monitoring of clinical sites and clinical research activities.
  7. Ability to provide training of clinical site personnel and other collaborators on all aspects of clinical data management.
  8. Ability to operate and maintain a specimen tracking system.
  9. Ability to operate and maintain a secure data storage system.
  10. Ability to distribute study data and metadata to NIH- and NIAID-designated repositories and other collaborators.


Technical Plan/Approach: appropriateness and adequacy of the plans for conducting all the activities described above.



Personnel/Management: adequacy, appropriateness and relevance of expertise, experience, qualifications, and availability of the key professional and technical staff with a project of similar size, scope, and complexity.



It is estimated that 60 Full-Time Equivalents (FTEs) will be required for each year of the proposed contract. For the purposes of this notice, a Full-Time Equivalent is one (1) person- whether contractor employee, subcontractor employee, or consultant-who works 2,080 hours per year.



It is anticipated that the Government may exercise Options for increased level of effort that may result from unanticipated increases in demand, with the services required under the Options to be of the same scope provided during the Base year. Should the Government elect to exercise any of the Options, the Options may be exercised within the Base period (and within each year of the proposed contract), up to a maximum of additional 90 FTEs.



Facilities/Resources/IT Security: adequacy and appropriateness of the facilities and resources dedicated to the project.



AI oversight: appropriateness and adequacy of the plans to ensure AI-enabled tools and systems are subject to documented human review and quality control.



Past Performance: Past performance is considered essential. In addition to demonstrating that an offeror has met the above qualifications, interested parties must identify at least three (3) other projects of similar size and complexity.



Page Limitations:


Interested qualified small business organizations should submit a tailored Capability Statement not to exceed 5 pages, excluding resumes. Capability Statements must not include links to internet web site addresses (URLs) or otherwise direct readers to alternate sources of information.



Font size must be 10 to 12 points. Spacing must be no more than 15 characters per inch. Within a vertical inch, there must be no more than six lines of text. Print margins must be at least one inch on each edge of the paper. Print setup should be single sided on standard letter size paper (8.5x 11in the U.S., A4 in outside the U.S.). All proprietary information should be marked as such.



Required Business Information:



  • UEI.
  • Company Name.
  • Company Address.
  • Company Point of Contact, Phone and Email address
  • Current GSA Schedules and/or Government-wide Acquisition Contracts (GWACs) appropriate to this Sources Sought.
  • Do you have a government-approved accounting system? If so, please identify the agency that approved the system.
  • Type of Company (i.e., small business, 8(a), woman owned, veteran owned, etc.) as validated via the System for Award Management (SAM) located at https://www.sam.gov/index.html. This indication should be clearly marked on the first page of your Capability Statement (preferably placed under the eligible small business concern’s name and address).


Number of Copies:



Please submit one (1) electric copy of your response as follows:



All Capability Statements sent in response to this Small Business Sources Sought notice must be submitted electronically (via e-mail) to Cindy Hargett, Contracting Officer, at cindy.hargett@nih.gov in Microsoft Word or Adobe Portable Document Format (PDF). The e-mail subject line must specify reference number 75N98026R00169.



Common Cut-off Date



Electronically submitted tailored capability statements are due no later than 3:00 PM (Eastern Time) on September 30, 2026. CAPABILITY STATEMENTS RECEIVED AFTER THIS DATE AND TIME WILL NOT BE CONSIDERED.



Disclaimer and Important Notes


This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities.



However, responses to this notice will not be considered adequate responses for a solicitation.



Confidentiality


No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).


Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Chemical, Biological, Radiological and Nuclear Advance Defense Enabling Network and Clinical Capability (CADENCC)
Solicitation # W911SR-26-9-CADENCC
The Department of the Army, through the Army Contracting Command Edgewood Contracting Division and the Joint Project Lead Enabling Technologies, is seeking preproposals for the Chemical, Biological, Radiological and Nuclear Advance Defense Enabling Network and Clinical Capability project. This initiative aims to accelerate clinical trial startups for CBRN defense readiness by implementing Master Protocols, utilizing innovative technologies for decentralized trial operations, and establishing a pre-positioned clinical trial site network. The project will primarily focus on Phase I and Phase II clinical trials for early treatment products, post-exposure prophylaxis, and pre-exposure prophylaxis, including those under the Animal Rule. This opportunity is issued under 10 USC 4022 Other Transaction Authority for a prototype project, with the potential for non-competitive follow-on production contracts for successful performers. Preproposals are due by 1500 hours on September 17, 2026, and must be limited to 10 pages. Evaluation will be based on technical merit, military relevance, technology readiness level 4 or above, regulatory compliance with FDA guidelines, and best overall value. Prospective awardees must be registered in the System for Award Management database.
W6QK Acc-Apg

POSTED

2 days ago

DEADLINE

in 1 day
View Details
NAICS: 541714
New
Federal
Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
Solicitation # 75A50126R00001_RFP_NPIVS_27
The Biomedical Advanced Research and Development Authority (BARDA) is soliciting proposals for the Vaccine Medical Countermeasures (MCMs) for Pandemic Influenza Preparedness and Response Program. The primary objective is to maintain a permanent readiness posture and a commercially sustainable warm-base production capacity for the rapid manufacture of vaccines, antigens, and adjuvants during public health emergencies. Contractors are required to produce these countermeasures against influenza and other viruses with pandemic potential, generate and submit all necessary analytical, nonclinical, clinical, and chemistry, manufacturing, and controls data to the FDA, and support rapid regulatory decisions. To be eligible, offerors must hold a U.S. influenza vaccine license or have developed an influenza vaccine as evidenced by a Biologics License Application submission. The contract is structured as an IDIQ with a five-year base period and a potential five-year option period, totaling a possible 120-month ordering period. Award decisions will be based on the Highest Technically Rated Offerors with a Fair and Reasonable Price methodology, with a significant emphasis on capabilities. Key requirements include strict adherence to CGMP guidelines, the implementation of comprehensive business and supply continuity plans, and the submission of surge manufacturing and supply chain readiness assessments. Deliverables include the preparation of candidate vaccine viruses and the management of complex logistics, including temperature-controlled shipping and specific packaging standards. Payment is processed quarterly via the Department of Treasury Invoice Processing Platform.
Barda - Aspr / Daappo / Barda Dcma

POSTED

5 days ago

DEADLINE

in 2 months
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health Niaid

Same awarding agency

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS